

Agenda Item	2.3 (i)
--------------------	----------------

Freedom of Information Status	Open
Reporting Committee	Performance and Finance Committee
Author	Georgia Pennells, Corporate Governance Officer
Chaired by	Reena Owen, Independent Member
Lead Executive Director (s)	Darren Griffiths, Director of Finance and Performance
Date of meeting	22 November 2022

Summary of key matters considered by the committee and any related decisions made.

Financial Position (Month Seven)

The Health Board should now be achieving a breakeven position following confirmation that the previously identified deficit of £24.4m would be funded by Welsh Government. The actual Month 7 variance was an overspend of £0.51m. The Year-To-Date plan at Month 7 should be breakeven but actual variance is an overspend of £3.70m. At the end of Month 7, funding for COVID Transition costs of £34.6m and the extraordinary pressures £19.04m remain anticipated allocations and are noted as a risk. There is a £13.0m overspend on the delegated position however, the vast majority of which is sat with Morriston service group, is almost £10.0m overspent after 7-months. There have been released opportunities from slippage on schemes and the agreement with Welsh Government around the balance sheet of £9.4m to achieve the £3.7m position. From a savings perspective there has been £34.1m worth saving schemes identified for this financial year and the recurrent impact of those is £27.1m – those are plans rather than delivered. In the past week further adjustments on the savings plan have been completed, where reds have been taken out and have given greater certainty on the greens

Key matters raised by members:

- The finance improvement director at Morriston hospital is to attend the December 2022 committee to provide a deeper context and further assurance as the health board moves into 2023.

Performance Report

Performance against the 4-hour access is currently below the outlined trajectory in October 2022. Emergency department 4-hour performance has deteriorated by 2.1% in October 2022 to 70.56% from 72.7% in September 2022. Single cancer pathway remains below the submitted trajectory however, is an improvement on previous months performance. Backlog figures have seen a continued increase in recent weeks and currently remain above the submitted recovery trajectory. There were on average 306 patients who were deemed clinically optimised but were still occupying a bed in one of the health board's hospital sites. Detailed work is being undertaken by the deputy chief operating officer to explore opportunities to reduce the number of clinically optimised patients in the hospital by implementing new pathways. The health board is above the Welsh Government profile target for hospital acquired infections. Each service group has developed detailed action plans which reinforces the quality and safety guidelines to support a reduction in infection rates.

<p><i>Key matters raised by members:</i></p> <ul style="list-style-type: none"> - Staggered launch of AMSR associated with capacity, financial and workforce risks. 	
Key risks and issues/matters of concern of which the board needs to be made aware.	
<p>Continuing healthcare performance report</p> <p>Staff recruitment remains problematic with carers leaving for jobs in different sectors. The impact of the paucity of registrants available to the care home sector has meant on occasions that a provider who has previously offered nursing beds has had to de-register nursing services. Care Home providers may need to consider a different approach regarding on-site availability of registered nurses. Significant work has been undertaken on reviewing the Mental Health & Learning Disabilities continuing healthcare performance position and establishing “moving forward” plans. This has included an external review of the team, which produced recommendations for change and improvement which have been built into the continuing healthcare action plan.</p> <p><i>Key matters raised by members:</i></p> <ul style="list-style-type: none"> - The financial position and sustainability issues in the care sector continues to escalate. 	
Delegated action by the committee.	
None identified.	
Main sources of information received.	
<ul style="list-style-type: none"> - Cancer performance presentation; - Financial monitoring return for month seven. 	
Highlights from sub-groups reporting into this committee.	
No reports received from sub-groups.	
Matters referred to other committees.	
Date of next meeting	20th December 2022



Agenda Item	2.4 (i)
--------------------	----------------

Freedom of Information Status	Open
Reporting Committee	Performance and Finance Committee
Author	Georgia Pennells, Corporate Governance Officer
Chaired by	Reena Owen, Independent Member
Lead Executive Director (s)	Darren Griffiths, Director of Finance and Performance
Date of meeting	25 October 2022
Summary of key matters considered by the committee and any related decisions made.	
Key risks and issues/matters of concern of which the board needs to be made aware.	
Delegated action by the committee.	
Main sources of information received.	
Highlights from sub-groups reporting into this committee.	
No reports received from sub-groups.	
Matters referred to other committees.	

There were no matters referred to other committees.	
Date of next meeting	22nd November 2022